Tag - Kg

Shares of Alpharma Inc. (NYSE:ALO) gained nearly half their value this morning and hit a new 52-week high following reports that the specialty pharmaceutical company had received a takeover bid by King Pharmaceuticals Inc. (NYSE:KG).

In a statement issued before the bell on Friday, Bristol, Tenn.-based King said it had submitted a proposal to acquire all of the outstanding shares of Alpharma common stock for $33 per share in cash – a 37% premium over Alpharma’s closing price on Aug. 21.

But, according to King, Alpharma of Bridgewater, N.J., declined the proposal. King was taking the matter public, it said, so that shareholders would be aware of the “compelling offer.”

By mid-morning, Alpharma is at $34.54, up $10.50 from Thursday’s close. More than 10 million shares have changed hands compared with an average three-month volume of 800,312 shares. The stock had traded between $17.55 and $28.67 during the past 52 weeks.

For detailed price information and news stories on Alpharma, click ALO.
 

Hooked on oxycodone, morphine, codeine or tramadol? Acura Pharmaceuticals (Nasdaq:ACUR) is on the way, intent on saving the world from addiction while defeating acute pain.

Acura wants to be the Superman of pain relief, but for now it’s just a Mighty Mouse in the making. As a development stage company, Palatine, Ill.-based Acura addresses what it terms the growing societal problem of prescription drug abuse. Its job is to make products that deter misuse but still ease discomfort. It has no revenue to date — only payments from a license agreement with King Pharmaceuticals (NYSE:KG), which agreed in October 2007 to market certain Acura products should they be approved for sale. 

Acura, actually, is just getting off the ground. Its shares moved onto Nasdaq in February after a reverse stock split, having traded previously on the OTC Bulletin Board. The company hoped to attract analyst coverage after its move to Nasdaq, but no analyst yet follows Acura. There also haven’t been presentations at investor conferences, so visibility into the company is limited.

But one thing is clear: becoming profitable depends on payments from King, and on the successful commercialization by King of future licensees of products using Acura’s Aversion Technology platform. The platform is key: Acura believes it has the power to develop a range of abuse-deterrent pain drugs. King expanded its arrangement in May, paying Acura $3 million for a license on a third Acura drug.

Acura’s agreement with King includes milestone payments for meeting goals of a late stage study on Acurox tablets — the company’s lead drug. An application for Acurox is expected to be submitted to the Food and Drug Administration for approval by the end of 2008. The most recent Acurox payment was $5 million in June.

Acurox is an immediate-release opioid analgesic that discourages misuse, including intravenous injection of dissolved tablets or capsules, nasal snorting of crushed tablets and swallowing pills in excessive numbers.

Mash a tablet and snort the powder, and your nose will burn. Try to separate . . .

Acura Pharmaceuticals (Nasdaq:ACUR)
Palatine, Ill.
http://www.acurapharm.com

52-week low/high: $5.79/$27
Shares Outstanding: 42.72 million
Market Capitalization: $331 million

More than 75 million Americans suffer from pain — more than the number of people with diabetes, heart disease and cancer combined. Prescription medications exist; however, the abuse of such, especially by younger people, complicates physicians’ ability and/or willingness to treat pain. Enter Acura Pharmaceuticals (Nasdaq:ACUR), a company that specializes in prescription drug abuse deterrents. 

The company has seen broad-based institutional interest as of late. According to Nasdaq.com, seven new positions were initiated as of March 31, 2008 in Acura, while eight existing investors increased their positions. On the flip side, only one position was decreased and sold out. Those who initiated new positions as of March 31 were UBS (NYSE:UBS), Merrill Lynch (NYSE:MER), Black Rock (NYSE:BLK), Wells Fargo (NYSE:WFC) and Deutsche Bank (NYSE:DB).

The Palatine, Ill.-based firm specializes in development of opioid pain medicines using what it calls Aversion technology, which is a patented platform designed to develop pharmaceutical products that are intended to relieve moderate to severe pain and deter common methods of prescription drug abuse (injection, nasal snorting and intentional swallowing). Acura’s lead product candidate is acurox — orally administered release tablets with oxycodone to treat severe pain.

In fact, Acura in conjunction with pharmaceutical company King Pharmaceuticals (NYSE:KG) recently reported positive results for a phase III study on the acurox tablets and expects to submit a new drug application to the FDA for acurox tablets by year end.

Acura also has a license agreement with King to develop opioid analgesic products using the aversion technology (opioid is a chemical used in drugs for pain relief). The two are currently jointly developing three immediate-release opioid analgesics using the aversion technology.

The alliance with King, consummated in December 2007, has proven to be a sagacious move, as the company is already realizing revenue accretion. In 2008, Acura recognized $17.1 million in revenues, adding to a strong first quarter.

For the first three months ended March 31, 2008, the latest quarter for which results were available, the company reported net income of $7.4 million, or $0.15 per, compared with a net loss of $9.2 million, or $0.26 per share for the same quarter in 2007.

Drilling down further into the financials, the company has just closed in on profitability. Acura swung to a profit in the fourth quarter of 2007. The company began generating positive cash flows from operations in 2007 and has been steadily increasing its cash position. As of April 30, 2008, the company had cash and cash equivalents of approximately $30 million with no term indebtedness.

Gross margins are higher than the industry at 100%, while the industry sits at 69%. Operating margin was 39.17% compared with -19.84% for the industry.

Varicose veins are not only an unsightly situation that many women fret about as they age, they can also create a painful medical problem. The recent strides in treating them, though, have led to downright ugly legal battles.

Vascular Solutions, Inc. (Nasdaq:VASC), which makes an array of products used in vascular medicine, is one of the players helping to revolutionize treatment of varicose veins using laser technology. The potential market for this small cap is large: more than 60 million Americans have cardiovascular disease, now the leading cause of death in the United States

Vascular Solutions’ lineup falls in five categories: vein products, to treat conditions such as varicose veins; hemostasis products, to halt bleeding; extraction catheters, to remove blood clots primarily after a heart attack; specialty catheters; and access products, to manage puncture sites.

Though the Minneapolis, Minn.-based company is caught up in a slew of patent-infringement battles, it appears to be progressing toward routinely turning a profit.

Since Vascular Solutions introduced its first device in 2000, yearly revenue has climbed to $52.9 million last year from $6.2 million, and its product list now exceeds 40.

In 2007, a 22% revenue rise was matched by a 22% decline in its stock price, reflecting not only the overall stock market retrenchment but also the uncertainty from Vascular Solutions’ legal woes.

Innovation in vascular medicine is on a fast track: laser therapy has reduced varicose vein treatment to a simple outpatient procedure from surgery with a hospital stay, but the risk associated with this progress includes a legal one for device makers. It is a chicken-or-egg situation, to determine who . . .